Beskrywing

Viscosupplementation is the term that describes the use of intraarticular hyaluronates for the treatment of pain in osteoarthritic joints. Viscosupplementation is a highly used palliative treatment for knee OA because of ease of application and theoretical ability to relieve symptoms by restoring and replenishing hyaluronate component into the knee joint. The global viscosupplementation market in terms of revenue is set to grow by US$ 2 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 8.7% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix. Growth in the geriatric population, increasing prevalence of knee osteoarthritis, rapid expansion of healthcare facilities in developing economies are expected to boost the market growth in the coming years.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for viscosupplementation. The global viscosupplementation market is segmented on the basis of product, application, region. Per produk, it is categorized into single-injection cycle, three-injection cycle, and five-injection cycle. The three-injection cycle segment held the largest market share in 2020. Deur aansoek, the viscosupplementation market is divided into knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, en ander. The knee osteoarthritis segment accounted for the largest market share in 2020. Based on region, the viscosupplementation market is divided into North America, Asiatiese Stille-Oseaan, Europa, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as Altergon Italia Srl, Anika Therapeutics Inc., Bioventus LLC, Bloomage Freda Biopharm Co. Bpk., Chugai Pharmaceutical Co. Bpk., Contipro a.s., Ferring Pharmaceuticals AS, Fidia Farmaceutici S.p.A., Kewpie Corporation, Lifecore Biomedical Inc., Meiji Holdings Co. Bpk., Sanofi S.A., Seikagaku Corporation, Zimmer Biomet Holdings Inc..

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the viscosupplementation market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Produk: single-injection cycle, three-injection cycle, and five-injection cycle
Toepassing: knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, en ander
Streek: Noord-Amerika, Asiatiese Stille-Oseaan, Europa, and Rest of the World (ROW)
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the global viscosupplementation market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the global viscosupplementation market looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Viscosupplementation Market by Product
4.1 Single-Injection Cycle
4.2 Three-Injection Cycle
4.3 Five-Injection Cycle
5. Viscosupplementation Market by Application
5.1 Knee Osteoarthritis
5.2 Hip Osteoarthritis
5.3 Shoulder Osteoarthritis
5.4 Ander
6. Viscosupplementation Market by Region
6.1 Noord-Amerika
6.2 Asiatiese Stille-Oseaan
6.3 Europa
6.4 Rest Of The World (Row)
7. Maatskappy profiele
7.1 Altergon Italia Srl
7.2 Anika Therapeutics Inc.
7.3 Bioventus LLC
7.4 Bloomage Freda Biopharm Co., Bpk.
7.5 Chugai Pharmaceutical Co. Bpk.
7.6 Contipro a.s.
7.7 Ferring Pharmaceuticals AS
7.8 Fidia Farmaceutici S.p.A.
7.9 Kewpie Corporation
7.10 Lifecore Biomedical, Inc.
7.11 Meiji Holdings Co., Bpk.
7.12 Sanofi S.A.
7.13 Seikagaku Corporation
7.14 Zimmer Biomet Holdings, Inc.
8. Bylaag
8.1 Oor StrategyHelix
8.2 Vrywaring